Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 FY26 with consolidated revenue of INR 3,960 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark delivered a strong Q3 FY26 with consolidated revenue of INR 3,960 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds. India formulation grew 22.1% YoY, outperforming the IPM, while the US business (ex-outlicensing) grew 4.1%. EBITDA margin came in at 23%, in line with guidance. Management highlighted the ramp-up of innovative assets (RYALTRIS, TEVIMBRA, BRUKINSA) and the Monroe facility restart as key growth levers. Guidance for FY26 remains strong, with expectations of US respiratory approvals in Q4 and a net cash positive balance sheet. Risks include delayed US approvals and working capital normalization.
ग्लेनमार्क ने वित्त वर्ष 2026 की तीसरी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कुल आय 3,960 करोड़ रुपये रही, जो पिछले साल की तुलना में 15.1% अधिक है। यह वृद्धि सभी बाजारों में बिक्री बढ़ने और विदेशी मुद्रा के अनुकूल प्रभाव से हुई। भारत में दवाओं की बिक्री 22.1% बढ़ी, जो पूरे बाजार से बेहतर है। अमेरिका में (लाइसेंसिंग को छोड़कर) 4.1% वृद्धि हुई। कंपनी का परिचालन लाभ (EBITDA) 23% रहा, जो अनुमान के अनुसार है। प्रबंधन ने नई दवाओं (RYALTRIS, TEVIMBRA, BRUKINSA) और मुनरो फैक्ट्री की शुरुआत को वृद्धि का मुख्य कारण बताया। आगे अमेरिका में सांस संबंधी दवाओं की मंजूरी और कर्ज मुक्त बैलेंस शीट की उम्मीद है। जोखिमों में अमेरिकी मंजूरी में देरी और कार्यशील पूंजी का सामान्यीकरण शामिल है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Delays in US FDA approvals for respiratory products
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Revenue Growth
22.1%
+22.1% YoY
India formulation business grew 22.1% YoY to INR 1,298.6 million, outperforming the IPM.
RYALTRIS Global Secondary Sales Growth
50%+
+50%+ YoY
RYALTRIS recorded global secondary sales growth of over 50% YoY, on track to become a $100M product.
Net Cash Position
INR 600 crore
N/A
Company remains net cash positive with gross debt of INR 600 crore and cash of INR 1,200 crore.
Working Capital Days
110 days
-15 days vs target
Net working capital days improved to ~110 days, ahead of the 115-day target for March 2026.
What Changed vs Last Quarter
NEW
EBITDA margin guidance of 23% sustainable
Management reiterated guidance of 23% EBITDA margin on a sustainable basis, with potential upside from new product approvals.
NEW
Net working capital days target of 115 by March 2026
Targeting net working capital days of 115 by end of FY26, with current levels at ~110 days.
NEW
US respiratory approvals expected in Q4 FY26
Expecting FLOVENT 44 and other respiratory product approvals in Q4, which will drive US growth.
UPDATED
Gross debt zero by March 2026
Company remains on track to achieve gross debt zero by March 2026.
DROPPED
India business Q3 run-rate of INR 1,150-1,200 crore
Management expects India formulation sales to return to INR 1,150-1,200 crore per quarter from Q3 FY26, with FY27 revenue exceeding INR 4,800 crore.
DROPPED
FY27 revenue guidance of INR 17,000-18,000 crore
Management guided for FY27 consolidated revenue of INR 17,000-18,000 crore, implying ~15% growth over FY26 run-rate.
DROPPED
EBITDA margin target of 23% moving to 25%+
EBITDA margin to trend towards 23% immediately and strengthen to 25%+ over time, driven by discontinuation of pre-collections and operating leverage.
NEW RISK
Delays in US FDA approvals for respiratory products
FLOVENT 44 approval is pending; any delay could impact Q4 US revenue growth.
NEW RISK
Currency depreciation impact on reported growth
Analyst questioned the quantum of currency benefit; management could not quantify, indicating potential overstatement of organic growth.
NEW RISK
Gross margin pressure from product mix
Excluding out-licensing income, gross margin was lower at 65% due to product mix; recovery depends on new approvals.
NEW RISK
Working capital normalization challenges
Despite progress, working capital days remain a focus; any slippage could impact cash flow targets.
RISK GONE
India distribution disruption from GST change
The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales. While management expects normalization, future regulatory changes could again disrupt the three-tier model.
RISK GONE
Recurrence of legacy balance sheet issues
Analysts questioned the frequency of write-offs (Monroe, litigation, India). Management assured no further corrections, but past unpredictability raises concerns about controls.
RISK GONE
Litigation cash outflows still pending
Management confirmed litigation cash outflows of slightly less than INR 800 crore over the next few years, which could pressure cash flows if not managed.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q3 FY25
Management expects emerging markets to record double-digit growth in FY26 on a constant currency basis.
Mentioned in Q1 FY26, Q4 FY25
Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.
Mentioned in Q1 FY25, Q3 FY25
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
Mentioned in Q1 FY25, Q2 FY25
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Fast read
Guidance and risk preview
Management reiterated guidance of 23% EBITDA margin on a sustainable basis, with potential upside from new product approvals.
FLOVENT 44 approval is pending; any delay could impact Q4 US revenue growth.
View Risks →